Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923366 | 1.00 | MC4R (0.62) | MC4RKMT2AALDH1A1TAAR1EPHX1 | |
| SCHEMBL13938122 | 1.00 | MC4R (0.62) | MC4RKMT2AALDH1A1TAAR1EPHX1 | |
| SCHEMBL3267496 | 1.00 | MC4R (0.62) | MC4RKMT2AALDH1A1TAAR1EPHX1 | |
| SCHEMBL3267409 | 1.00 | MC4R (0.62) | MC4RKMT2AALDH1A1TAAR1EPHX1 | |
| SCHEMBL22178742 | 0.82 | MC4R (0.88) | MC4RKMT2AALDH1A1TAAR1EPHX1 | |
| Hydrochloric Acid SCHEMBL22160650 | 0.81 | MC4R (0.86) | MC4RKMT2AALDH1A1TAAR1POLB | |
| SCHEMBL4597877 | 0.81 | TAAR1 (0.65) | KMT2AALDH1A1TAAR1EPHX1TRPV1 | |
| SCHEMBL13743588 | 0.80 | TAAR1 (0.77) | KMT2AALDH1A1TAAR1EPHX1TRPV1 | |
| SCHEMBL12420662 | 0.79 | MTNR1A (0.56) | MC4RKMT2AALDH1A1EPHX1GAA | |
| Hydrochloric Acid SCHEMBL28291774 | 0.77 | MC4R (0.75) | MC4RKMT2AALDH1A1TAAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326833-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H LEE MOFFITT CANCER CT & RES (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7135483-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060223853-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | THE PROCTER GAMBLE CO. | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223853-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | ABCC1, ABCB1, ABCB11 | MC4R 3004/4885KMT2A 3027/4885ALDH1A1 540/4885 |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | MC4R 4163/4885KMT2A 2975/4885ALDH1A1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.